Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient


  • Text size: A A A
  • Circadin
  • Recent news

    • Slenyto (PedPRM) is now available in Denmark!
    • Slenyto (PedPRM) is now also available in Iceland!
    • Slenyto (PedPRM) is now available in Switzerland!
  • Partners

    Partners